Episode Description
In this episode, Tom Hickey, Director of Therapeutic Strategy at Novotech, joins Citeline to discuss how the clinical research landscape is evolving for liver disease, particularly in hepatitis B, NASH, and hepatocellular carcinoma (HCC).
Tom shares how Novotech, a leading global CRO with a biotech-focused model, supports sponsors through every phase of hepatology clinical development. From adaptive trial strategies and AI-enhanced site selection to deep regional integration across Asia-Pacific, the US, and Europe, Novotech helps sponsors navigate complexity with confidence.
Tune in to learn how Novotech’s flexible operating model, advanced therapeutic experience, and commitment to innovation are helping biotech sponsors accelerate the development of next-generation liver disease treatments.